D&D Pharmatech (347850.KQ)

KRW 47200.0

(0.21%)

Long Term Debt Summary of D&D Pharmatech

  • D&D Pharmatech's latest annual long term debt in 2023 was 5.12 Billion KRW , down -20.3% from previous year.
  • D&D Pharmatech's latest quarterly long term debt in 2024 Q2 was 4.94 Billion KRW , down 0.0% from previous quarter.
  • D&D Pharmatech reported annual long term debt of 6.42 Billion KRW in 2022, down -13.91% from previous year.
  • D&D Pharmatech reported annual long term debt of 7.46 Billion KRW in 2021, up 48.73% from previous year.
  • D&D Pharmatech reported quarterly long term debt of 4.94 Billion KRW for 2024 Q2, down 0.0% from previous quarter.
  • D&D Pharmatech reported quarterly long term debt of - KRW for 2023 Q1, down -100.0% from previous quarter.

Annual Long Term Debt Chart of D&D Pharmatech (2023 - 2019)

Historical Annual Long Term Debt of D&D Pharmatech (2023 - 2019)

Year Long Term Debt Long Term Debt Growth
2023 5.12 Billion KRW -20.3%
2022 6.42 Billion KRW -13.91%
2021 7.46 Billion KRW 48.73%
2020 5.01 Billion KRW 159.95%
2019 1.93 Billion KRW 0.0%

Peer Long Term Debt Comparison of D&D Pharmatech

Name Long Term Debt Long Term Debt Difference
HLB Co., Ltd. 17.93 Billion KRW 71.446%
iNtRON Biotechnology, Inc. 258.29 Million KRW -1882.471%
BINEX Co., Ltd. 5.57 Billion KRW 8.206%
Bioneer Corporation 12.5 Billion KRW 59.035%
Anterogen.Co.,Ltd. - KRW -Infinity%
MEDIPOST Co., Ltd. 6.99 Billion KRW 26.795%
CrystalGenomics, Inc. 29.88 Billion USD 82.868%
Helixmith Co., Ltd 151.68 Million KRW -3275.937%
Chabiotech Co.,Ltd. 95.06 Billion KRW 94.614%
Medy-Tox Inc. 1.22 Billion KRW -317.723%
Peptron, Inc. 4.5 Billion KRW -13.792%
Amicogen, Inc. 70.65 Billion KRW 92.753%
Genexine, Inc. 22.68 Billion KRW 77.424%
HLB Therapeutics Co.,Ltd. 1.84 Billion KRW -178.266%
LegoChem Biosciences, Inc. 528.37 Million KRW -869.131%
ALTEOGEN Inc. 1.24 Billion KRW -309.893%
PharmaResearch Co., Ltd. 970.71 Million KRW -427.509%
SillaJen, Inc. 8.13 Billion KRW 37.061%
JETEMA, Co., Ltd. 60 Billion KRW 91.466%
OliX Pharmaceuticals,Inc 35.36 Billion KRW 85.519%
Genomictree Inc. 97.51 Million KRW -5151.076%
MedPacto, Inc. 1.68 Billion KRW -203.544%
EASY BIO,Inc. 30 Billion KRW 82.931%
GI Innovation, Inc. 2.9 Billion KRW -76.33%